PartnershipApr 13, 2026, 04:07 PM
Sana & Mayo Clinic Partner on Type 1 Diabetes Therapy SC451
AI Summary
Sana Biotechnology, Inc. and Mayo Clinic have announced a strategic collaboration to advance SC451, Sana's investigational hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. This partnership aims to accelerate the development, validation, and standardization of protocols for SC451, leveraging Mayo Clinic's multidisciplinary expertise. Mayo Clinic will also make an equity investment in Sana, reflecting a shared commitment to improving care for patients with type 1 diabetes.
Key Highlights
- Sana Biotechnology and Mayo Clinic announced a strategic collaboration.
- The collaboration focuses on advancing SC451, a cell therapy for type 1 diabetes.
- Mayo Clinic will make an equity investment in Sana Biotechnology.
- The goal is to accelerate development and access to SC451.
- Sana aims to start a clinical trial for SC451 this year.